We validated our findings by integrating data from the GSE database of NPC clinical samples, identifying two target-small molecule interactions-PTGS2-Acacetin and CCND1-Asperglaucide—as potentially the most effective therapeutic targets for NPC. Here, PTGS2 is linked to nasopharyngeal carcinoma.